Indivior ends PAM drug collab with Addex ahead of Supernus merger

Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs).

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

1. Fierce Biotech - Biotech 7h ago
   Indivior ends PAM drug collab with Addex ahead of Supernus merger ↗